Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2024

Original Article

GLP-1 receptor agonists and cardiorespiratory outcomes in patients with COPD

Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD.

Thorax

Citation & Authors

Thorax. 2024;79(11):1017-1023.

Fu-Shun Yen; Chih-Cheng Hsu; James Cheng-Chung Wei; Fuu-Jen Tsai; Yuhan Huang; Teng-Shun Yu; Chii-Min Hwu

ABSTRACT · RESEARCH SUMMARY

Research summary

This matched Taiwanese National Health Insurance cohort analyzed patients with type 2 diabetes and COPD. GLP-1 receptor agonist use was associated with lower risks of death (aHR 0.46; 95% CI 0.38–0.56), cardiovascular events, noninvasive and invasive ventilation, and bacterial pneumonia. Several subgroup and treatment-duration analyses supported the association, but the evidence remains observational.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗